Humalog ® (insulin lispro)

För fullständig produktresumé för Humalog® se FASS

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Humalog® (insulin lispro): Tid-effekt-profil

Insulin lispro har en snabbare start, en tidigare topp och kortare aktivitetstid än Humulin® S

SE_cFAQ_LIS209_TIME_ACTIVITY_PROFILE
cFAQ
cFAQ
SE_cFAQ_LIS209_TIME_ACTIVITY_PROFILE
en-GB

Humalog® (insulin lispro) : Time Activity Profile

Insulin lispro has a more rapid onset, earlier peak, and shorter duration of activity than regular human insulin.

Detailed Information

The PK and PD properties of Insulin lispro reflect a compound that

  • has a rapid onset of action of approximately 15 minutes
  • achieves peak blood levels 30 to 70 minutes following SC injection, and
  • has a short duration of activity of 2 to 5 hours.1

Despite the differences, the total absorption of Insulin lispro (as measured by area under curve for insulin concentration over a period of time) is similar to regular human insulin.2

Clinically, Insulin lispro produces a greater effect within the first 2 hours resulting in more rapid utilization of carbohydrates than regular human insulin. Insulin lispro suppresses hepatic glucose production in the postinjection period to a significantly greater extent than regular human insulin. This is an important mechanism in preventing postprandial hyperglycemia.3

Insulin lispro was absorbed more quickly than regular human insulin after injection of 0.2 U/kg immediately before a high carbohydrate meal in patients with type 1 diabetes mellitus (Serum Insulin lispro and insulin levels after subcutaneous injection of regular human insulin or Insulin lispro (0.2 U/kg) immediately before a high carbohydrate meal in 10 patients with Type 1 Diabetes Mellitus*).2

Serum Insulin lispro and insulin levels after subcutaneous injection of regular human insulin or Insulin lispro (0.2 U/kg) immediately before a high carbohydrate meal in 10 patients with Type 1 Diabetes Mellitus*2

* Baseline insulin concentration was maintained by infusion of 0.2 mU/min/kg human insulin.

The time course of insulin lispro action may vary in different individuals or at different times in the same individual and is dependent on dose, site of injection, blood supply, temperature and physical activity.1

References

1Humalog [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

3Bruttomesso D, Pianta A, Mari A, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes. 1999;48(1):99-105. http://dx.doi.org/10.2337/diabetes.48.1.99

Glossary

insulin lispro = Humalog® (insulin lispro) 100 units/mL

PD = pharmacodynamic

PK = pharmacokinetic

Regular Human Insulin = Humulin® R U-100 (insulin human) 100 units/mL

Datum fӧr senaste ӧversyn 2021 M03 30


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Klicka för att chatta är tillgänglig

Klicka för att chatta är offline

Skriv din fråga till oss